Table A3.
Adjusted Association Between Baseline Conditions and Chemotherapy-Induced Peripheral Neuropathy
| Grades 2-4 Neuropathy | Grades 3-4 Neuropathy | |||||||
|---|---|---|---|---|---|---|---|---|
| No, No. (%) | Yes, No. (%) | OR (95% CI)* | P* | No, No. (%) | Yes, No. (%) | OR (95% CI)* | P* | |
| 1,150 (82) | 251 (18) | 1,280 (91) | 121 (9) | |||||
| Diabetes with chronic complications† | ||||||||
| No | 864 (83.7) | 169 (16.3) | Reference | 952 (92.2) | 81 (7.8) | Reference | ||
| Yes | 82 (74.5) | 28 (25.5) | 2.13 (1.31 to 3.46) | .002 | 97 (88.2) | 13 (11.8) | 1.73 (0.90 to 3.32) | .10 |
| Diabetes with or without chronic complications | ||||||||
| No | 864 (83.6) | 169 (16.4) | Reference | 952 (92.2) | 81 (7.8) | Reference | ||
| Yes | 286 (77.7) | 82 (22.3) | 1.67 (1.23 to 2.27) | .001 | 328 (89.0) | 40 (11.0) | 1.61 (1.07 to 2.42) | .02 |
| Liver Disease | ||||||||
| No | 1,005 (83) | 212 (17) | Reference | 1,112 (91) | 105 (9) | Reference | ||
| Yes | 145 (79) | 39 (21) | 1.27 (0.85 to 1.89) | .24 | 168 (91) | 16 (9) | 0.98 (0.56 to 1.73) | .95 |
| Hypothyroidism | ||||||||
| No | 966 (82.6) | 204 (17.4) | Reference | 1,072 (91.6) | 98 (8.4) | Reference | ||
| Yes | 184 (79.7) | 47 (20.3) | 1.12 (0.77 to 1.63) | .56 | 208 (90.0) | 23 (10.0) | 1.05 (0.64 to 1.74) | .84 |
| Hypercholesterolemia | ||||||||
| No | 604 (83.0) | 124 (17.0) | Reference | 671 (92.2) | 57 (7.8) | Reference | ||
| Yes | 546 (81.1) | 127 (18.9) | 1.07 (0.80 to 1.43) | .66 | 609 (90.5) | 64 (9.5) | 1.23 (0.83 to 1.84) | .30 |
| Hypertension | ||||||||
| No | 365 (82.0) | 80 (18.0) | Reference | 410 (92.1) | 35 (7.9) | Reference | ||
| Yes | 785 (82.1) | 171 (17.9) | 0.97 (0.71 to 1.31) | .83 | 870 (91.0) | 86 (9.0) | 1.15 (0.75 to 1.77) | .51 |
| Varicella zoster | ||||||||
| No | 1,119 (82.0) | 245 (18.0) | Reference | 1,247 (91.4) | 117 (8.6) | Reference | ||
| Yes | 31 (83.8) | 6 (16.2) | 0.82 (0.33 to 2.03) | .67 | 33 (89.2) | 4 (10.8) | 1.18 (0.40 to 3.48) | .77 |
| Kidney disease | ||||||||
| No | 979 (81) | 224 (19) | Reference | 1,093 (91) | 110 (9) | Reference | ||
| Yes | 171 (86) | 27 (14) | 0.73 (0.46 to 1.14) | .16 | 187 (94) | 11 (6) | 0.65 (0.34 to 1.25) | .19 |
| Peripheral vascular disease | ||||||||
| No | 1,040 (81.8) | 231 (18.2) | Reference | 1,158 (91.1) | 113 (8.9) | Reference | ||
| Yes | 110 (84.6) | 20 (15.4) | 0.71 (0.43 to 1.19) | .19 | 122 (93.8) | 8 (6.2) | 0.62 (0.29 to 1.31) | .21 |
| Autoimmune diseases‡ | ||||||||
| No | 1,080 (81.7) | 242 (18.3) | Reference | 1,204 (91.1) | 118 (8.9) | Reference | ||
| Yes | 70 (88.6) | 9 (11.4) | 0.49 (0.24 to 1.02) | .06 | 76 (96.2) | 3 (3.8) | 0.32 (0.10 to 1.03) | .06 |
*
Odds ratios and P values adjusted for age, race (black/white/other), sex, cancer stage/risk, date of initial enrollment, and planned treatment time according to the protocol (at or above v below the median), and stratified by treatment type (docetaxel v paclitaxel) and platinum treatment (yes/no).
†
The comparison is between patients with diabetes plus complications versus patients with no diabetes. Patients with diabetes without complications are excluded from this analysis.
‡
Includes Sjögren’s syndrome, lupus, rheumatoid arthritis, scleroderma, mixed connective tissue disease, dermatomyositis, polymyositis, vasculitis, and giant cell arteritis.